MedTrace Logo

Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

NCT00990743 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-10-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether SYL040012 is safe for the treatment of ocular hypertension and glaucoma.

Conditions

Interventions

DRUG

SYL040012

Administration of single and multiple doses of SYL040012 in ophthalmic drops solution

Sponsors & Collaborators

  • Sylentis, S.A.

    lead INDUSTRY

Principal Investigators

  • Belen Sadaba, MD, PhD · Clínica Universitaria de Navarra

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00990743 on ClinicalTrials.gov